StabiLux Biosciences Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Private

  • Employees
  • 10

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $554K

  • Investors
  • 11

StabiLux Biosciences General Information

Description

Developer of high-brightness fluorophores designed for biomedical researchers to detect rare biomarkers. The company's technology offers proprietary dyes with tunable brightness, antibody conjugation, photostability, water solubility, and multi-color channel compatibility, enabling biomedical researchers to identify rare events and viruses with increased sensitivity using existing flow cytometry equipment.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 600 South Wagner Road
  • Ann Arbor, MI 48103
  • United States
+1 (906)
Primary Industry
Other Pharmaceuticals and Biotechnology
Other Industries
Discovery Tools (Healthcare)
Specialty Chemicals
Corporate Office
  • 600 South Wagner Road
  • Ann Arbor, MI 48103
  • United States
+1 (906)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

StabiLux Biosciences Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
10. Later Stage VC 16-May-2024 $554K Completed Generating Revenue
9. Later Stage VC 01-Apr-2022 Completed Generating Revenue
8. Later Stage VC (Series A) 19-Mar-2021 Completed Product In Beta Test
7. Grant 02-Sep-2020 Completed Startup
6. Later Stage VC 12-May-2020 Completed Startup
5. Later Stage VC 01-Apr-2020 Completed Startup
4. Seed Round 29-Sep-2017 Completed Startup
3. Grant 15-Sep-2017 Completed Startup
2. Grant 31-Dec-2016 $241K Completed Startup
1. Grant 01-Jul-2015 $225K Completed Startup
To view StabiLux Biosciences’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

StabiLux Biosciences Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

StabiLux Biosciences Investors (11)

Investor Name Investor Type Holding Investor Since Participating Rounds
Ann Arbor SPARK Accelerator/Incubator Minority
John Lilly Strategic Insights Corporation Minority
Lateral Capital Management Venture Capital Minority
Alligator Holdings Venture Capital Minority
Invest Detroit Ventures Corporate Venture Capital Minority
You’re viewing 5 of 11 investors. Get the full list »

StabiLux Biosciences FAQs

  • When was StabiLux Biosciences founded?

    StabiLux Biosciences was founded in 2014.

  • Where is StabiLux Biosciences headquartered?

    StabiLux Biosciences is headquartered in Ann Arbor, MI.

  • What is the size of StabiLux Biosciences?

    StabiLux Biosciences has 10 total employees.

  • What industry is StabiLux Biosciences in?

    StabiLux Biosciences’s primary industry is Other Pharmaceuticals and Biotechnology.

  • Is StabiLux Biosciences a private or public company?

    StabiLux Biosciences is a Private company.

  • What is StabiLux Biosciences’s current revenue?

    The current revenue for StabiLux Biosciences is .

  • How much funding has StabiLux Biosciences raised over time?

    StabiLux Biosciences has raised $1.85M.

  • Who are StabiLux Biosciences’s investors?

    Ann Arbor SPARK, John Lilly Strategic Insights, Lateral Capital Management, Alligator Holdings, and Invest Detroit Ventures are 5 of 11 investors who have invested in StabiLux Biosciences.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process